These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34986867)

  • 1. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
    Hong JY; Cho HJ; Sa JK; Liu X; Ha SY; Lee T; Kim H; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park HC; Kang TW; Rhim H; Lee SJ; Cristescu R; Lee J; Paik YH; Lim HY
    Genome Med; 2022 Jan; 14(1):1. PubMed ID: 34986867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
    Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
    Huffman BM; Singh H; Ali LR; Horick N; Wang SJ; Hoffman MT; Metayer KA; Murray S; Bird A; Abrams TA; Biller LH; Chan JA; Meyerhardt JA; McCleary NJ; Goessling W; Patel AK; Wisch JS; Yurgelun MB; Mouw K; Reardon B; Van Allen EM; Zerillo JA; Clark JW; Parikh A; Mayer RJ; Schlechter B; Ng K; Kumar S; Del Vecchio Fitz C; Kuperwasser C; Hanna GJ; Coveler AL; Rubinson DA; Welsh EL; Pfaff K; Rodig S; Dougan SK; Cleary JM
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
    Agdashian D; ElGindi M; Xie C; Sandhu M; Pratt D; Kleiner DE; Figg WD; Rytlewski JA; Sanders C; Yusko EC; Wood B; Venzon D; Brar G; Duffy AG; Greten TF; Korangy F
    Cancer Immunol Immunother; 2019 Apr; 68(4):599-608. PubMed ID: 30688989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
    Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A9
    Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
    J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
    Yarchoan M; Gane EJ; Marron TU; Perales-Linares R; Yan J; Cooch N; Shu DH; Fertig EJ; Kagohara LT; Bartha G; Northcott J; Lyle J; Rochestie S; Peters J; Connor JT; Jaffee EM; Csiki I; Weiner DB; Perales-Puchalt A; Sardesai NY
    Nat Med; 2024 Apr; 30(4):1044-1053. PubMed ID: 38584166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions.
    Doumba PP; Nikolopoulou M; Gomatos IP; Konstadoulakis MM; Koskinas J
    BMC Gastroenterol; 2013 Jan; 13():17. PubMed ID: 23331458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
    Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
    Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
    Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
    Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD38 marks the exhausted CD8
    Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
    Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.
    Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Clin J Gastroenterol; 2020 Oct; 13(5):867-872. PubMed ID: 32020539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.